## AMENDMENT TO THE CLAIMS

The listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Currently amended) A pharmaceutical composition comprising gabapentin initially containing less than 0.5% by weight of a corresponding lactam with respect to the weight of the gabapentin; more than 20 ppm of an anion of a mineral acid with respect to the weight of the gabapentin; and [having] which exhibits a pH in the range of 6.8 to 7.3,

in which composition, the conversion of gabapentin to its corresponding lactam does not exceed 0.2% by weight of gabapentin after one year of storage at 25 °C and 60% humidity [the conversion of gabapentin to its corresponding lactam does not exceed 0.2% by weight of gabapentin].

2. (Previously presented) The pharmaceutical composition of claim 1, wherein the pH is in the range of 7.0 to 7.2.

3. (Previously presented) The pharmaceutical composition of claim 1 further comprising at least one adjuvant.

4. (Currently amended) The pharmaceutical composition of claim 3, wherein [said] the adjuvant is selected from the group consisting of [modified maize starch,] sodium croscarmelose, glycerol behenic acid ester, methacrylic acid co-polymers [(types A and C)], anion exchangers, titanium dioxide, silica gel[s], hydroxypropylmethylcellulose, polyvinylpyrrolidone, [crospovidon,] poloxamer 407, poloxamer 188, sodium starch glycolate, copolyvidone, maize starch, cyclodexterin, lactose, talc, co-polymers of dimethylamino-methacrylic acid and neutral methacrylic acid ester.

5. (Currently amended) Gabapentin [which contains] initially containing less than 0.5% of [the] a corresponding lactam, [and] more than 20 ppm but does not exceed [less than] 100 ppm of [the] an anion of a mineral acid, and [which has] and a pH between 6.8 and 7.3, [and]

in which conversion of gabapentin to its corresponding lactam does not exceed 0.2% by weight of gabapentin after one year at 25°C and 60% relative humidity[, the conversion of gabapentin to its corresponding lactam does not exceed 0.2% by weight of gabapentin].

6. (Previously presented) The pharmaceutical composition of claim 4, wherein said silica gel is Aerosil 200.

7. (New) The pharmaceutical composition according to claim 4, wherein the polyvinylpyrrolidone is crospovidone.

8. (New) The pharmaceutical composition according to claim 4, wherein the maize starch is modified maize starch.

9. (New) The pharmaceutical composition according to claim 1, wherein the anion of the mineral acid is present in an amount of more than 20 ppm but less than 213 ppm.

10. (New) The pharmaceutical composition according to claim 1 further comprising a basic agent.

11. (New) The pharmaceutical composition according to claim 10, wherein the basic agent is tributylamine, sodium methoxide, trihexylamine, tripropylamine, sodium bicarbonate, tetramethylammonium hydroxide, and tetrabutylammonium hydroxide.